Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update
August 15, 2022 16:10 ET
|
Homology Medicines, Inc.
- On Track for Updates on pheEDIT and juMPStart Programs by End of 2022 - - Prioritized Pipeline, Shifting Resources to HMI-103 PKU Gene Editing Trial in Adults While Pausing Enrollment in HMI-102...
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
August 11, 2022 16:05 ET
|
Homology Medicines, Inc.
- Candidate Showed Ability to Target Central Nervous System and Peripheral Organs Following a Single I.V. Administration in MLD Model, a Key Differentiator from Available Treatments and Product...
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver
July 05, 2022 08:30 ET
|
Homology Medicines, Inc.
AAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE)...
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
June 29, 2022 08:00 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences: ...
Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU
June 13, 2022 08:00 ET
|
Homology Medicines, Inc.
- Company Increased Risk-Mitigation Strategies, Including a Steroid-SparingImmunosuppression Regimen - BEDFORD, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a...
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
May 18, 2022 06:00 ET
|
Homology Medicines, Inc.
- Additional Data at ASGCT Annual Meeting Demonstrate Precision of HR-Based Approach with Genome-Wide Integration Assays Confirming On-Target Editing and No Off-Target Events - - New Data from...
Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
May 16, 2022 16:15 ET
|
Homology Medicines, Inc.
- $130 Million in Non-Dilutive Capital Strengthened Financial Position - - Presentations at Upcoming ASGCT Annual Meeting Include First-Time Details of Mechanism of Action of Nuclease-Free Gene...
Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting
May 02, 2022 16:56 ET
|
Homology Medicines, Inc.
- Multiple Presentations Feature HMI-103 Phase 1 Investigational Therapy for PKU, Including Genome-Wide Integration Assays to Confirm No Off-Target Editing - - New Data from GTx-mAb Program Support...
Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President
April 21, 2022 08:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., Chief Scientific Officer, has...
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 23, 2022 16:10 ET
|
Homology Medicines, Inc.
- Formed New AAV Manufacturing and Innovation Business with Oxford Biomedica to Leverage Homology’s Process Development and Manufacturing Capabilities - - Received $130 Million Non-Dilutive Capital...